Pscilly

Compass Psilocybin Launch Plan: COMP360 Eyes Early 2027 Rollout

By · Published

COMPASS Pathways used an investor conference on Wednesday, Nov. 18, to give its most detailed picture yet of how it plans to bring the first psilocybin-based prescription treatment to American patients. Speaking at the Jefferies Global Healthcare Conference, company leaders said they intend to be launch-ready by the end of this year and expect a commercial launch in the first half of 2027, if regulators sign off.

The drug, COMP360, is the company's proprietary synthetic psilocybin, developed for treatment-resistant depression. Compass completed its New Drug Application with the FDA on Nov. 9 after a rolling review, and Chief Executive Kabir Nath called the moment a transformational inflection point for the company.

The regulatory road ahead

Nath said Compass expects the FDA to accept the filing and assign a review deadline soon, and that the company holds a Commissioner's National Priority Voucher, a program meant to speed reviews. He acknowledged that no new vouchers have been issued recently but said Compass has no reason to think the agency will back away from its commitment to move quickly. The company said it does not expect an advisory committee meeting but will be prepared if one is called.

FDA approval alone will not put COMP360 in clinics. Chief Commercial Officer Lori Englebert explained that the DEA must then reschedule the drug, a step that typically takes about 90 days, though an executive order signed in April encourages faster action on psychedelics. Compass expects COMP360 to land in Schedule III, the same category as Janssen's esketamine nasal spray SPRAVATO. After that, states must update their own drug schedules. Englebert said about 93% of the U.S. population lives in states that have committed to rescheduling within 30 days of federal action.

Riding the esketamine network

A central piece of the company's pitch is that it does not need to build a new treatment system. Englebert said there are about 8,500 SPRAVATO-certified treatment sites in the U.S., growing by roughly 500 a quarter, and she expects more than 9,000 by the time COMP360 launches. Chief Financial Officer Teri Loxam said those sites would not need different rooms or staff to administer COMP360, and Englebert said the average site currently sees about one SPRAVATO patient a day, leaving room for more.

Compass expects a safety program similar to SPRAVATO's, including about two hours of monitoring by a health care provider after each session. The treatment is given in a clinic and is not something patients take home.

The company also contrasted dosing schedules. According to Englebert, COMP360 is expected to require two to four sessions a year, compared with 35 to 55 for SPRAVATO, which she said places a heavy burden on patients and caregivers. Compass described efficacy and tolerability between the two as broadly comparable.

Market size and pricing

Compass estimates about 4 million Americans live with treatment-resistant depression. Englebert said SPRAVATO currently reaches about 100,000 of them while generating more than $2 billion a year in sales, and could reach about 250,000 patients at peak. Compass said it is confident it can price COMP360 above SPRAVATO's annualized cost of $50,000 to $65,000, and plans to launch with about 100 sales representatives plus reimbursement and medical teams. The company expects some early insurance hurdles and said a patient support program is ready to help with affordability.

Compass also addressed competition. Usona Institute recently filed its own psilocybin application for major depressive disorder, a broader population. Compass argued that Usona's program would not compete directly with COMP360's treatment-resistant focus and said it has identified possible patent issues with Usona's approach. Usona did not respond to those claims at the conference.

For now, COMP360 remains investigational. Psilocybin is still a Schedule I substance under federal law, and the timeline Compass described depends on decisions by the FDA, the DEA and individual states.

U.S. treatment-resistant depression: patients vs. current treatment reach
Americans with TRD (est.)4,000,000 patients
SPRAVATO patients today100,000 patients
SPRAVATO projected peak250,000 patients

Company estimates presented by Compass Pathways at the Jefferies Global Healthcare Conference, Nov. 18, 2026.

On Pscilly

Published
November 18, 2026